These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 1651554

  • 1. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
    Sinkule JA, Rosen ST, Radosevich JA.
    Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
    [Abstract] [Full Text] [Related]

  • 2. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.
    Cancer Res; 1992 Oct 15; 52(20):5693-700. PubMed ID: 1382845
    [Abstract] [Full Text] [Related]

  • 3. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

  • 4. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma.
    Yeh MY, Roffler SR, Yu MH.
    Int J Cancer; 1992 May 08; 51(2):274-82. PubMed ID: 1568795
    [Abstract] [Full Text] [Related]

  • 5. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells.
    Froesch BA, Stahel RA, Zangemeister-Wittke U.
    Cancer Immunol Immunother; 1996 Jan 08; 42(1):55-63. PubMed ID: 8625367
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
    Sivam GP, Martin PJ, Reisfeld RA, Mueller BM.
    Cancer Res; 1995 Jun 01; 55(11):2352-6. PubMed ID: 7757986
    [Abstract] [Full Text] [Related]

  • 7. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates.
    Hebert C, Norris K, Sauk JJ.
    J Drug Target; 2003 Feb 01; 11(2):101-7. PubMed ID: 12881196
    [Abstract] [Full Text] [Related]

  • 8. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
    Yang HM, Reisfeld RA.
    Proc Natl Acad Sci U S A; 1988 Feb 01; 85(4):1189-93. PubMed ID: 3422487
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM.
    Cancer Res; 1995 Jun 01; 55(11):2357-65. PubMed ID: 7757987
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer.
    Yu DS, Chu TM, Yeh MY, Chang SY, Ma CP, Han SH.
    J Urol; 1988 Aug 01; 140(2):415-21. PubMed ID: 3398165
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.
    King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, Hellström KE, Trail PA.
    Bioconjug Chem; 1999 Aug 01; 10(2):279-88. PubMed ID: 10077478
    [Abstract] [Full Text] [Related]

  • 12. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
    Greenfield RS, Kaneko T, Daues A, Edson MA, Fitzgerald KA, Olech LJ, Grattan JA, Spitalny GL, Braslawsky GR.
    Cancer Res; 1990 Oct 15; 50(20):6600-7. PubMed ID: 2208122
    [Abstract] [Full Text] [Related]

  • 13. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.
    Science; 1993 Jul 09; 261(5118):212-5. PubMed ID: 8327892
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
    Biddle WC, Haruta Y, Seon BK, Henderson ES, Sarcione EJ.
    Leuk Res; 1989 Jul 09; 13(8):699-707. PubMed ID: 2529399
    [Abstract] [Full Text] [Related]

  • 15. The effect of anti-alpha-fetoprotein-adriamycin conjugate on a human hepatoma.
    Galun E, Shouval D, Adler R, Shahaar M, Wilchek M, Hurwitz E, Sela M.
    Hepatology; 1990 Apr 09; 11(4):578-84. PubMed ID: 1691730
    [Abstract] [Full Text] [Related]

  • 16. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
    Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB.
    Int J Cancer; 2001 Aug 15; 93(4):590-600. PubMed ID: 11477565
    [Abstract] [Full Text] [Related]

  • 17. Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity.
    Ogden JR, Leung K, Kunda SA, Telander MW, Avner BP, Liao SK, Thurman GB, Oldham RK.
    Mol Biother; 1989 Aug 15; 1(3):170-4. PubMed ID: 2604916
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS.
    Cancer Res; 1990 Oct 15; 50(20):6608-14. PubMed ID: 2208123
    [Abstract] [Full Text] [Related]

  • 19. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens.
    Shouval D, Adler R, Wands JR, Hurwitz E, Isselbacher KJ, Sela M.
    Proc Natl Acad Sci U S A; 1988 Nov 15; 85(21):8276-80. PubMed ID: 2460865
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO, Isaksson M, Willner D, Hellström I, Hellström KE, Trail PA.
    Cancer Res; 1997 Oct 15; 57(20):4530-6. PubMed ID: 9377565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.